2015 is out and 2016 is in…does your firm have what it takes to make 2016 the best year of your law practice? Most of us are reflecting on what we accomplished compared to what we had hoped. What will you tackle next time around? How will you brave the storms? If you’re thriving, how […]
NEWS
FDA Concludes Invokana, SGLT2 Inhibitors, Pose Serious Risks
Friday, December 4, the FDA announced that its concerns about SGLT2 inhibitors were confirmed. FDA Concludes Invokana, SGLT2 Inhibitors, Pose Serious Risks. In May 2015, the FDA announced it was investigating the SGLT2 inhibitors (which include brands Invokana, Farxiga, Jardiance, Xigduo, and Glyxambi) for a connection to ketoacidosis (acid in the blood) and severe urinary tract […]
How to Diversify a Mass Tort Inventory
If you want to position yourself optimally for success with mass torts, you need to diversify. How do we do that? One of the best ways to diversify is to categorize potential cases by the stage of the litigation. The three stages are: Stage I – No centralized docket; FDA warning communications likely but not […]
How Does a Mass Tort Work?
Before claims ever become part of a mass tort, they often start as a hunch. Perhaps an FDA recall is released, a new study comes out on risks of a medication or device, or maybe a few lawyers notice that a drug’s documentation does not quite seem complete. As more lawyers, claimants, and experts are […]
Building Your Intake and Lead Conversion System
Establishing a Foundation Regardless of industry, many business have old and unconverted leads. Leads often express interest and then seemingly vanish. Why does this happen? There could be any number of reasons. In the case of a law firm, people might not be inclined to answer your calls because they think you are a bill […]